









Markets
/
Stocks
/
nasdaq-xair
/

Beyond Air Inc

XAIR

0.722USD

+0.032+4.68%

Close 03/27, 16:00（ET）Quotes delayed by 15 min

74.54KMarket Cap

LossP/E TTM



Beyond Air Inc

0.722

+0.032+4.68%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Beyond Air Inc

Currency: USD Updated: 2026-03-27

Key Insights

Beyond Air Inc's fundamentals are relatively stable, with industry-average ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 127 out of 208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.75.In the medium term, the stock price is expected to remain stable.Despite a very weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Beyond Air Inc's Score

Industry at a Glance

Industry Ranking

127 / 208

Overall Ranking

301 / 4542

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Beyond Air Inc Highlights

StrengthsRisks

Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. Its segments include Beyond Air, Beyond Cancer, and NeuroNos. It has received United States Food and Drug Administration approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. The Company is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria. It has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder and other neurological disorders. Its product pipeline includes LungFit PH, LungFit PRO, LungFit GO, and others.

Growing

The company is in a growing phase, with the latest annual income totaling USD 3.71M.

Undervalued

The company’s latest PE is -0.16, at a low 3-year percentile range.

Held by The Vanguard

Star Investor The Vanguard holds 60.44K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.87.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

7.750

Target Price

+936.10%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Beyond Air Inc is 5.35, ranking 200 out of 208 in the Healthcare Equipment & Supplies industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 2.19M, representing a year-over-year increase of 104.66%, while its net profit experienced a year-over-year increase of 43.71%.

Score

Industry at a Glance

Previous score

5.35

Change



Financials

5.32

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.89

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.72

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

4.72

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Beyond Air Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Beyond Air Inc is 7.66, ranking 69 out of 208 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -0.16, which is -97.29% below the recent high of -0.00 and -143.54% above the recent low of -0.40.

Score

Industry at a Glance

Previous score

7.66

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 127/208

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Beyond Air Inc is 7.60, ranking 125 out of 208 in the Healthcare Equipment & Supplies industry. The average price target is 8.50, with a high of 14.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

7.60

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

7.750

Target Price

+936.10%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

115

Total

Median

Average

Company name

Ratings

Analysts

Beyond Air Inc

XAIR

Medtronic PLC

MDT

Stryker Corp

SYK

Dexcom Inc

DXCM

Zimmer Biomet Holdings Inc

ZBH

Abbott Laboratories

ABT

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Beyond Air Inc is 6.00, ranking 165 out of 208 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 0.89 and the support level at 0.61, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.74

Change

0.26

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.003

Neutral

RSI(14)

34.369

Neutral

STOCH(KDJ)(9,3,3)

20.258

Neutral

ATR(14)

0.054

Low Volatility

CCI(14)

-170.743

Sell

Williams %R

74.899

Sell

TRIX(12,20)

-1.263

Sell

StochRSI(14)

54.519

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.742

Sell

MA10

0.772

Sell

MA20

0.804

Sell

MA50

1.064

Sell

MA100

1.134

Sell

MA200

1.977

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Beyond Air Inc is 3.00, ranking 135 out of 208 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 21.71%, representing a quarter-over-quarter increase of 20.17%. The largest institutional shareholder is The Vanguard, holding a total of 60.44K shares, representing 0.57% of shares outstanding, with 59.93% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Alyeska Investment Group, L.P.

833.78K

+9.84%

Balyasny Asset Management LP

297.44K

-35.92%

Carey (Robert F.)

277.67K

-0.00%

Lisi (Steven A)

174.44K

+1.38%

Bleichroeder LP

86.49K

+134.29%

Geode Capital Management, L.L.C.

42.98K

+2.55%

The Vanguard Group, Inc.

Star Investors

104.41K

+43.82%

Avenue Capital Group

54.81K

-33.12%

Wealth Effects LLC

33.76K

+142.75%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Beyond Air Inc is 1.74, ranking 176 out of 208 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.52. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Beyond Air Inc’s latest ESG disclosure is at an average level in the Healthcare Equipment & Supplies industry, showing no material impact on overall risk.